Filings Flow: Sciclone Pharmaceuticals Inc: Jade Park Investments Ltd Opened Big New Position

Filings Flow: Sciclone Pharmaceuticals Inc: Jade Park Investments Ltd Opened Big New Position

The New Jade Park Investments Ltd Holding in Sciclone Pharmaceuticals Inc

Jade Park Investments Ltd filed with the SEC SC 13D/A form for Sciclone Pharmaceuticals Inc. The form can be accessed here: 000094787116001675. As reported in Jade Park Investments Ltd’s form, the filler as of late owns 0.017% or 8,888 shares of the Health Care–company.

Sciclone Pharmaceuticals Inc stake is a new one for the and it was filed because of activity on November 14, 2016. We feel this shows Jade Park Investments Ltd’s positive view for the stock.

Sciclone Pharmaceuticals Inc Institutional Sentiment

Latest Security and Exchange filings show 128 investors own Sciclone Pharmaceuticals Inc. The institutional ownership in Q3 2015 is high, at 68.25% of the outstanding shares. This is decreased by 3075290 the total institutional shares. 34839438 were the shares owned by these institutional investors. In total 13 funds opened new Sciclone Pharmaceuticals Inc stakes, 49 increased stakes. There were 26 that closed positions and 52 reduced them.

Americafirst Capital Management Llc is an institutional investor bullish on Sciclone Pharmaceuticals Inc, owning 87524 shares as of Q3 2015 for less than 0.01% of its portfolio. Ranger Investment Management Lp owns 130840 shares or 0.05% of its portfolio. CT Nantahala Capital Management Llc have 0.16% of their stock portfolio for 170218 shares. Further, Matarin Capital Management Llc reported stake worth less than 0.01% of its US stock portfolio. The CA Sensato Investors Llc owns 1564682 shares. Sciclone Pharmaceuticals Inc is 2.03% of the manager’s US portfolio.

Business Profile

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 1.18 in 2016 Q2. Its up 0.06, from 1.12 in 2016Q1. The ratio increased, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.

Renaissance Techs Limited Liability Co accumulated 0.03% or 1.16 million shares. National Bank Of Ny Mellon Corporation holds 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 597,540 shares. Principal Group last reported 351,202 shares in the company. Profund Lc has 0.01% invested in the company for 10,830 shares. California Public Employees Retirement Systems owns 135,200 shares or 0% of their US portfolio. State Board Of Administration Of Florida Retirement System reported 121,705 shares or 0.01% of all its holdings. Citadel Advisors Ltd Llc holds 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 41,007 shares. Moreover, Ranger Invest Mngmt Lp has 0.08% invested in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 99,900 shares. Strs Ohio last reported 57,200 shares in the company. New York State Teachers Retirement reported 41,221 shares or 0% of all its holdings. California State Teachers Retirement Systems holds 105,084 shares or 0% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 4,238 shares in the company. Denver Advisors Lc holds 10,678 shares or 0.01% of its portfolio. Barclays Public Limited Com has 0% invested in the company for 91,462 shares. Blackrock Fund Advisors holds 4.50M shares or 0.01% of its portfolio.

Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 12 insider sales for $10.10 million net activity. Another trade for 31,083 shares valued at $323,574 was made by Meng Chuncai on Friday, August 12. $421,605 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) shares were sold by Zhao Hong. On Monday, August 29 Cheung Wilson Wai-Shun sold $19,370 worth of the stock or 1,872 shares. Blobel Friedhelm sold $371,892 worth of stock or 40,000 shares. Hawkins Richard J sold $1.24 million worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Friday, August 12. $340,221 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) was sold by Xie Lan on Friday, August 12. CHANG NANCY T had sold 25,040 shares worth $257,896.

The stock increased 5.08% or $0.5 during the last trading session, hitting $10.35. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has declined 19.14% since April 13, 2016 and is downtrending. It has underperformed by 23.07% the S&P500.

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $530.33 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.82 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.

More notable recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on October 28, 2009, also Prnewswire.com with their article: “SciClone Reports Third Quarter 2016 Financial Results” published on November 09, 2016, Prnewswire.com published: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On …” on October 25, 2016. More interesting news about SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) were released by: Quotes.Wsj.com and their article: “DOW JONES, A NEWS CORP COMPANY” published on February 12, 2011 as well as Nasdaq.com‘s news article titled: “Sciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 …” with publication date: August 19, 2016.

According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”

SCLN Company Profile

SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment